Skip To The Main Content
Other PDA Sites
PDA Letter
PDA Journal
PDA Connect
PDA Technical Report Portal
Get Involved
Become a Volunteer
Volunteer Opportunities
PDA Covid-19 Information
Join/Renew
|
Login
Login to Your PDA Account
Sign in
Don't have an account yet?
Create an Account
Forgot your username or password?
Recover account
Parenteral Drug Association
Connecting People, Science and Regulation
®
Parenteral Drug Association
Connecting People, Science and Regulation
®
Home
Events
Training
Topic Areas
Aseptic Processing & Sterilization
Biopharmaceuticals & Biotechnology
Manufacturing Science
Quality & Regulatory
Supply Chain & Outsourcing
Publications
Bookstore
PDA Journal
PDA Letter
Technical Reports
Global Community
Chapters
Interest Groups
Membership Directory
Member Resources
PDA Connect
Standards
Volunteer Opportunities
Technical Advisory Boards
Foundation
Join PDA
Front Page
About
About the PDA Letter
Advertising Opportunities
Contact Us
Regional Editions
Multimedia
Videos
Podcast
Infographics
Photostream
Archives
Free
Members Only
Full PDF
Submit
Risk-Benefit Analysis More of NCA Scope
Quality & Regulatory
{{Title}}
Remove
Oct 1, 2018
by
Rebecca Stauffer, PDA
(?)
On May 15, PDA submitted comments concerning the EU's template for GMP noncompliance statements.
You need to
Login to view the full article
. Please
Login
. Not a Member?
Join
today!
PDA Members Save Substantially
Join PDA/become a member
log in